Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know. Sluggish growth for Novo Nordisk's GLP-1 drugs caused the company to again reduce its ...
The Federal Trade Commission has raised concerns about Novo Nordisk’s attempt to outbid Pfizer to acquire obesity startup ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results